SciCross is happy to announce a new collaboration focused on modelling the human blood-brain-barrier using innovative in vitro and stem cell approaches. The project is a collaboration between the University of Skövde, Biolamina, 3Dtro, AstraZeneca and SciCross.
SciCross has contributed to work that will be presented at the European Congress of Immunology 2015, held in Vienna. The titles are ‘Risk factors of anti-drug antibodies (ADA) occurrence in multiple sclerosis ‘ and ‘Antibodies against interferon beta and natalizumab in European multiple sclerosis patients’. This work has been conducted in the scope of the ABIRISK project.
SciCross has received a grant from the Swedish innovation agency VINNOVA for development of innovative methods to reduce drug immunogenicity.
SciCross collaborators within the ABIRISK project will present results at the Scandinavian Society of Immunology meeting in Iceland later this year. The title is “Development of Antidrug Antibodies in Multiple Sclerosis Cohorts in Europe – Overview of Interferon Beta and Natalizumab Cases Tested for ADA in Different Countries”
SciCross has joined the IMI ABIRISK consortia, focused on understanding the mechanisms and consequences of drug immunogenicity of biopharmaceuticals. The project runs until November 2017 and has a total budget of approximately 33M euro.